We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Kaleido Biosciences Inc (KLDO) USD0.001

Sell:$4.25 Buy:$4.30 Change: $0.01 (0.23%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.01 (0.23%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.01 (0.23%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its Microbiome Metabolic Therapies (MMTs) is designed to drive the function and distribution of the microbiomes existing microbes in order to decrease or increase the production of metabolites to certain bacteria in the microbiome community. The Company is also advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with unmet patient needs. The Company utilizes its discovery and development platform to study MMTs in microbiome samples to rapidly advance MMT candidates into clinical studies in healthy subjects and patients. Its KB195 is the lead MMT candidate for development in the treatment of patients with urea cycle disorders. The Company is conducting a Phase II clinical trial under an Investigational New Drug Application (IND).

Contact details

18 Crosby Dr
United States
+1 (617) 6749000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$188.19 million
Shares in issue:
42.58 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Theo Melas-Kyriazi
    Chairman of the Board
  • Daniel Menichella
    President, Chief Executive Officer, Director
  • William Duke
    Chief Financial Officer
  • Jerald Korn
    Chief Operating Officer, General Counsel, Company Secretary
  • Johan Van Hylckama Vlieg
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.